Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com or call (609) 325-4668
Oncology Best Practice™:
Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast Cancer
July 2017 - October 2017
The expanding arsenal of targeted therapies available for the treatment of patients with hormone receptor-positive metastatic breast cancer has allowed clinicians to hone management approaches and personalize care. While novel therapies and combinations—such as those using available oral CDK4/6 inhibitors—may benefit patients with breast cancer, they also add markedly to the complexity of care. The provision of expert guidance regarding the most appropriate and efficacious incorporation of CDK4/6 inhibitors into clinical management strategies for hormone-receptor positive, metastatic breast cancer can help the multidisciplinary team to apply state-of-the-art evidence to treatment practice. This, in turn, can help to optimize treatment efficacy and minimize potential adverse events for patients who may be candidates for these therapies.
This activity will bring renowned experts in the medical management of breast cancer directly to your practice sites to provide key insights and perspectives to breast cancer management teams. The practical case-based format of the program will focus on the incorporation of recent practice-changing evidence on CDK4/6 inhibitors by multidisciplinary teams in the context of managing real-world clinical scenarios. Importantly, the collegial atmosphere of Grand Rounds/Tumor Boards and small group settings will allow for open, fluid interaction with experts in the field, and participants will have the opportunity to have some of their most pressing patient case dilemmas addressed. Indeed, the patient will remain the focus of this activity via practical assessments of how individual characteristics impact diagnosis, clinical decision-making, and the provision of quality care.
This activity is directed toward medical oncologists who treat or manage patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, researchers, pharmacists and other healthcare professionals interested in the treatment or management of these tumors are also invited to participate.
At the conclusion of this activity, participants should be better prepared to:
Joyce O’Shaughnessy, MD
Co-Director of Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
The US Oncology Network
Dallas, TX New York, NY
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018